The FDA’s advisory panel voted in opposition to expanded use of Talzenna/Xtandi for prostate most cancers and UGN-102 for recurrent bladder most cancers, citing security and efficacy considerations.
America Meals and Drug Administration’s (FDA) Oncologic Medication Advisory Committee (ODAC) has casted their votes on the utilization of two most cancers therapies for the remedy of each non–homologous recombination restore (HRR)–mutant metastatic castration-resistant prostate most cancers (mCRPC) and recurrent, low-grade, intermediate-risk non-muscle-invasive bladder most cancers (NMIBC) affected person populations, respectively.
In keeping with the official United States FDA web site (www.fda.gov), the ODAC features as an skilled panel that evaluates scientific information on the protection and efficacy of each investigational and permitted drug merchandise supposed for most cancers remedy. Based mostly on its assessments, the committee gives suggestions to the USA FDA Commissioner to help regulatory decision-making.
As famous on the web site, the committee consists of 13 voting members chosen for his or her experience in areas corresponding to normal oncology, pediatric oncology, hematologic oncology, immunologic oncology, biostatistics and associated fields. As well as, the committee could embody a non-voting consultant from the pharmaceutical trade, who contributes an trade viewpoint to the dialogue with out collaborating within the voting course of.
Lately, the ODAC hosted a regulatory assembly through which they casted their votes for the chance/profit profile of two most cancers therapies.
For sufferers with non-HRR-mutated mCRPC, the panel unanimously voted eight to zero in opposition to the chance/profit profile of Talzenna (talazoparib) when mixed with Xtandi (enzalutamide), primarily based on information from the section 3 TALAPRO-2 trial.
Moreover, the ODAC additionally voted 5 to 4 in opposition to the chance/profit profile of UGN-102 (mitomycin for intravesical [within the bladder] resolution) in sufferers with recurrent, low-grade, intermediate-risk NMIBC, primarily based on information from the section 3 ENVISION and ATLAS trials.
Here’s what you’ll want to learn about every regulatory determination from the FDA’s ODAC.
ODAC’s Vote on the Threat/Profit Profile of Talzenna/Xtandi in non-HRR-Mutant mCRPC
Though the ODAC voted unanimously in opposition to the chance/profit profile of Talzenna plus Xtandi in non-HRR-mutant mCRPC, the remedy mixture is at the moment FDA-approved for the HRR-mutated mCRPC affected person inhabitants, primarily based on the TALAPRO-2 trial outcomes, as of June 2023. Nonetheless, following this approval, a supplemental new drug software was submitted to the regulatory company looking for approval for the remedy mixture within the all-comers mCRPC affected person inhabitants, that means the approval wouldn’t be restricted to HRR mutation standing.
Of the 1,018 sufferers with first-line mCRPC who had been enrolled within the TALAPRO-2 trial, 805 had been part of the HRR-unselected inhabitants and 230 had been part of the HRR-mutated solely inhabitants. Sufferers within the HRR-mutated inhabitants confirmed a major radiographic progression-free survival and total survival profit with the Talzenna plus Xtandi remedy. Contrarily, within the HRR-unselected inhabitants, though a radiographic progression-free survival profit was noticed, the general survival profit was much less outlined.
The FDA cited considerations that the non-HRR–mutated/unknown subgroup was not utterly outlined, nor was it formally examined for efficacy. Furthermore, the regulatory company emphasised that therapies in biomarker-negative populations should be extra formally evaluated.
There was additionally elevated toxicity noticed with the investigative mixture within the non-mutated affected person group, together with greater charges of grade 3 (extreme) and 4 (life-threatening) uncomfortable side effects, critical treatment-related occasions and purple blood cell transfusions. There have been additionally incidences of myelodysplastic syndrome and acute myeloid leukemia — results of remedy —reported.
It’s primarily based on these much less efficient outcomes within the non-HRR–mutated/unknown affected person inhabitants, in addition to the elevated toxicity, that the ODAC voted in opposition to the chance/profit profile of Talzenna plus Xtandi in non-HRR-mutant mCRPC.
ODAC’s Vote on the Threat/Profit Profile of UGN-102 in Recurrent, Low-Grade, Intermediate-Threat NMIBC
On the identical day, the FDA’s ODAC voted 5 to 4 in opposition to the general danger/profit profile of UGN-102 for the remedy of recurrent, low-grade, intermediate-risk NMIBC. This comes after a brand new drug software was submitted by UroGen Pharma to the FDA in August 2024 for remedy with UGN-102 on this affected person inhabitants; information from the section 3 ENVISION trial and the ATLAS examine supported the appliance.
In the course of the assembly, numerous consultants voiced their help and hesitation for voting for or in opposition to remedy with UGN-102. Those that voted in opposition to the remedy touched on the brief three-month full response finish level and lack of a full randomized trial, whereas those that voted in favor of the remedy highlighted that UGN-102 has the chance to profit sufferers who are usually not optimum surgical candidates, noting the drug’s potential to delay or keep away from surgical procedure.
“Whereas we’re upset by at the moment’s final result, we proceed to imagine our scientific information help UGN-102 for the remedy of recurrent LG-IR-NMIBC, a illness with no FDA-approved therapies,” Liz Barrett, president and CEO of UroGen, mentioned in a information launch following the vote from the FDA’s ODAC. “The FDA rigorously considers the impartial recommendation from ODAC, and we look ahead to working with the FDA as they full their assessment of the appliance for UGN-102.”
Notably, the ATLAS examine was terminated early, and ENVISION information grew to become the first proof for brand spanking new drug software submission. Within the ENVISION trial, sufferers with low-grade, intermediate-risk NMIBC had been handled with weekly instillations of UGN-102 for six weeks and achieved a 79.6% full price at three months. Moreover, the 12-month period of response was 82.3%, and relating to security, most uncomfortable side effects had been delicate to average, with dysuria as the commonest occasion.
There are at the moment no FDA-approved therapies that at the moment exist for this affected person inhabitants.
For extra information on most cancers updates, analysis and training, don’t neglect to subscribe to CURE®’s newsletters right here.
